The idea that activation of AMPK might be useful in treatment of disorders of whole body energy balance such as obesity and Type 2 diabetes, which appears to have been first proposed in 1999 [83], led to a drive towards the development of AMPK activators by pharmaceutical and biotechnology companies. The gene discussed is PRKAB1; the disease is obesity due to melanocortin 4 receptor deficiency.